Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says
Material to help providers and patients understand scientific issues can inspire more confidence in the products, exec says.
You may also be interested in...
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.
US FDA asks for comments on whether the policy employed for small molecule generics also should apply to biosimilars.
Substituting a biosimilar for a reference product is a state issue and outside agency's purview, FDA says.